Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner

Beta-Blockers for Acute Myocardial Infarction

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

The Quality Improvement Support Collaborative has issued a practice advisory and fact sheet about the COMMIT/CCS-2 trial on beta blocker use for myocardial infarction within 24 hours of admission to the hospital. The goal of the Collaborative is to improve the 30-day outpatient mortality for myocardial infarction (MI) patients.

The Collaborative consists of the Agency for Healthcare Research and Quality (AHRQ), the American College of Cardiology (ACC), American Heart Association (AHA), Centers for Medicare and Medicaid Services (CMS), and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO).

Select to access:

American College of Cardiology Foundation
American Health Association
Agency for Healthcare Research and Quality
Centers for Medicare & Medicaid Services
Joint Commission of Healthcare Organizations

May 2005

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care